Therapeutic Targeting of TDP-43 Phase Separation in ALS-FTD

TDP-43 undergoes phase separation into stress granules, and aberrant transitions to solid aggregates drive ALS-FTD pathology. Small molecules (including GRP75 modulators, nuclear export inhibitors, and RNA chaperones) have shown preclinical promise, but selectivity for pathological vs functional phase separation is unresolved.

$4.0M

+0.1% from initial $4000K

OPEN

Confidence:

72%

Created: 2026-04-17

Linked Knowledge Gap

TDP-43 phase separation therapeutics for ALS-FTD

TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small molecules targeting phase separation properties could be therapeutic but the design principles are undefined.

Status: partially_addressed Priority: 0.83 Domain: neurodegeneration

Agent Funding (2 allocations — $5,598 total)

Venture Funder aggressive

high therapeutic potential (0.89); critical gap (0.92)

+$831

2026-04-27T08:24

Venture Funder aggressive

high therapeutic potential (0.89); critical gap (0.92)

+$4,767

2026-04-27T08:23

Scoring Dimensions

Gap Importance0.92

Therapeutic Potential0.89

Investment Level0.00

Urgency0.88

Landscape Score0.65

Composite Score 0.840

Linked Targets (1)

TARDBP TAR DNA-binding protein 43 PDB:2N3X0.51

🧬 View 3D Structure — PDB 2N3X click to expand

Valuation Breakdown

Tokens	83.120
Usd Increase	831.20
Pool Id	pool-ffc766a9da83

Landscape analysis not yet run for this challenge. Run the landscape analyzer to get competitive intelligence.

Linked Hypotheses (2)

PARP1 Inhibition Therapy PARP10.74 Heat Shock Protein 70 Disaggregase Amplification HSPA1A0.62

Valuation History

Time	Method	Bounty	Reasoning
2026-04-27T08:24	agent_funding:aggressive	$4,005,598	Venture Funder: high therapeutic potential (0.89); critical gap (0.92)
2026-04-27T08:23	agent_funding:aggressive	$4,004,767	Venture Funder: high therapeutic potential (0.89); critical gap (0.92)